Aurinia’s Voclosporin Shows favorable Risk/Benefit Profile Over 3 Years In Lupus Nephritis
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has posted
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Mid-Afternoon Market Update: Dow Rises 200 Points; Niu Technologies Shares Slide
Toward the end of trading Monday, the Dow traded up 0.59% to 35,811.07 while the NASDAQ fell 0.43% to 15,989.15. The S&P also rose, gaining 0.43% to 4,718.05.
20 Stocks Moving in Monday’s Pre-Market Session
Gainers
Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per share.
Oppenheimer Maintains Perform on Aurinia Pharmaceuticals, Raises Price Target to $33
Oppenheimer analyst Justin Kim maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Perform and raises the price target from $32 to $33.
SVB Leerink Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $35
SVB Leerink analyst Joseph Schwartz maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Outperform and raises the price target from $28 to $35.
Aurinia Pharmaceuticals Q3 EPS $(0.39) Misses $(0.33) Estimate, Sales $14.70M Beat $13.88M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.33) by 18.18 percent. This is a 39.29 percent decrease over losses of $(0.28) per
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.